NOVEMBER 2020
Inhalation 1-2-3 A brief update from Inhaltion Magazine.
 
 
Astech
 
perspective

UoDD, DDU or DCU?
imageWithin the safety and efficacy testing of inhaled drugs, the terms Uniformity of Delivered Dose, Delivered Dose Uniformity or Dose Content Uniformity are used, depending on the pharmacopoeia. While broadly similar, a different sequence of sampling is required to meet these guidelines. When selecting an automation solution, you must be able to change collection and waste fire patterns simply and easily. Astech's Relovex® software allows simple set-up of waste fire and sample collection profiles. Additionally, Relovex® provides a fully traceable and 21 CFR Part 11 compliant digital record.

Astech Projects
UK: +44 1928 571797
astechprojects.co.uk
 
Experic
 
in focus

imageDevelopment of HFA-152a as an environmentally sustainable propellant for pressurized metered dose inhalers
Regulations currently do not place restrictions on the use of HFA-134a or HFA-227ea for pressurized metered dose inhalers (pMDIs). However, they have the potential to adversely impact the supply chain through rationing or loss of industrial product feedstocks used as inputs for medical product manufacturing. Further, individuals and companies are seeking ways to reduce their environmental impacts, with carbon footprints. This provides motivation to adopt alternative propellants for pressurized metered dose inhalers. Yet the interests of the patient must be foremost in any approach to change. In addition, essential criteria for a new propellant include environmental sustainability, safety, functionality and economics. A number of materials have been considered as potential propellants for pMDIs. HFA-152a is under investigation and, to date, has shown an attractive combination of environmental and formulation performance properties, which are discussed in this October article.
 
Astech
 
feature

imageInhaled administration of drugs to animals in pharmaceutical research
Studies characterizing the toxicity of drugs (and, ideally, non-clinical efficacy studies) dose animals via the most clinically relevant route. While oral or injected dosing of animals is straightforward, inhaled administration of drugs presents technical and logistical challenges. This article provides an overview of considerations and industry practices for performing non-clinical studies in support of inhaled drug development. Topics include selection of test species, generation of the test atmosphere and its presentation to animals, aerosol characterization, dosimetry and pulmonary deposition of inhaled test materials. Lung deposition of the inhaled drug depends upon aerosol properties, anatomy and the breathing pattern of the test species.
 
Inhalation Subscription
 
image

imageInformation on upcoming industry events
Click for information on the following industry events:
  • The DDL2020 Christmas Lectures

Please visit the calendar on Inhalation's website for more conferences, which may change from live to virtual formats and have new dates due to COVID-19.
 
Inhalation Subscription
 
 
Questions about Inhalation, contact Vicki Schuman, Editor at vschuman@cscpub.com.
w: Inhalation Magazine • e: inhalationmag@cscpub.com
 
Copyright © 2020 Inhalation Magazine. All rights reserved.
 

 
This email was sent to you from inhnews@cscpub2.com. To ensure delivery of these emails in your inbox,
please add us to your safe sender list. Privacy Policy • Unsubscribe

CSC Publishing • 1155 Northland Dr • St Paul, MN 55120